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INTRODUCTION
============

Sodium balance, extracellular volume, and blood pressure are maintained by the tight control of the activity of the epithelial sodium channel (ENaC)[\*](#fn1){ref-type="fn"} ([@bib34]). We have recently identified a membrane-bound serine protease that acts as channel-activating protease, namely CAP1 ([@bib31], [@bib32]; [@bib35]). This regulation defines a novel extracellular signaling pathway, which appears to be highly conserved throughout evolution from *Xenopus* (xCAP1) ([@bib31]) to mouse ([@bib35]), rat ([@bib1]), and human ([@bib39]). CAP1 activates ENaC through its extracellular serine protease activity, as evidenced by patch-clamp experiments ([@bib7]). The activation of ENaC by CAP1 can be mimicked by external addition of trypsin, showing that both CAP1 and trypsin act via the same pathway. Aprotinin, an inhibitor of serine proteases, can block this effect ([@bib31]; [@bib35]). In epithelial cell lines, like the *Xenopus* kidney cell line (A6), ENaC appears to be constitutively activated through the presence of endogenously expressed serine proteases, since basal transepithelial Na^+^ transport cannot be further activated by addition of trypsin ([@bib31]). However, the base line Na^+^ transport can be inhibited by the addition of aprotinin on the apical side of the cell and this inhibition can be reversed by the addition of trypsin ([@bib31]). In *Xenopus* kidney cells, up to 90% of the amiloride-sensitive electrogenic Na^+^ transport can be blocked by aprotinin (50 μM) ([@bib31]), whereas the mouse mpkCCD~cl4~ cell line (derived from the cortical collecting duct; [@bib3]) appears to be only 50% sensitive to aprotinin ([@bib35]). These findings suggest that ENaC activation is achieved by either a constitutive, serine protease--independent mechanism or, alternatively, that the activation depends on more than one serine protease with different sensitivity to aprotinin and that acts in combination within the same cell. The mechanism by which serine proteases like CAP1 activates ENaC is not yet understood. CAP1 leads to a very substantial increase in the open probability of the Na^+^ channel, whereas the number of channels at the cell surface is either unchanged ([@bib31]) or even diminished ([@bib35]).

The activity of ENaC is tightly controlled by hormones, including aldosterone and vasopressin (for review see [@bib34]). Components of the aldosterone-dependent signaling pathway have been identified recently. Aldosterone rapidly induced the expression of Sgk1 kinase (serum- and glucocorticoid-regulated kinase), a member of the PKB-AKT family of serine-threonine kinases ([@bib37]). When coexpressed in *Xenopus laevis* oocytes, Sgk1 stimulates ENaC activity by 2--3-fold ([@bib6]; [@bib19]). In *Xenopus* oocytes, Sgk1 increases cell surface expression of ENaC without changing its open probability ([@bib2]; [@bib17]). Recently, it has been demonstrated that the phosphorylation of Nedd4-2, an ubiquitin protein ligase, by Sgk1 may regulate epithelial sodium channel cell surface expression in the *Xenopus* oocyte system ([@bib9]). It was further demonstrated that the phosphorylation of Nedd4-2 decreases its affinity for ENaC, thereby diminishing ENaC endocytosis and/or degradation ([@bib9]; [@bib29]). These data provided evidence for the missing link between aldosterone binding to its receptor, transcription activation of an aldosterone-induced protein (Sgk1) and the molecular mechanism leading to an increased cell surface expression of ENaC.

The aims of the present study were twofold: (a) to test the interaction between two regulatory pathways that can activate ENaC through extracellular signaling via CAPs and intracellular signaling via Sgk1, and (b) to identify further putative membrane-bound serine proteases able to activate ENaC; in particular, to search for an aprotinin-resistant protease that could account for the pharmacological data observed in the mouse CCD cell line.

We demonstrate here the existence of three channel-activating proteases, namely mouse channel--activating protease, mCAP1, mCAP2, and mCAP3 within the same kidney cell. Whereas mCAP2 is inhibited by aprotinin as well as mCAP1, mCAP3 is not significantly inhibited by this serine protease inhibitor. Each of these membrane-bound serine proteases increases ENaC-mediated I~Na~ and potentiates the effect mediated by Sgk1.

MATERIALS AND METHODS
=====================

Identification and Isolation of Full-length Clones
--------------------------------------------------

### Mouse CAP2:

Partial mCAP2 sequence was identified by RT-PCR using degenerated oligonucleotides and total RNA extracted from mpkCCD~cl4~ cells as described previously ([@bib35]). The primers used were as follows: D1 (sense) 5′-AA(AG)TT(CT)CCITGGCA(AG)GT-3′, nt +118 to +134; D2 (antisense) 5′-CC(AG)CA(CT)TC(AG)TCICCCCA-3′, nt +743 to +727; D3 (antisense) 5′-CCIGC(AG)CA(AGT)ATCAT (AG)TC-3′, nt +629 to +613; according to xCAP1 (5′ and 3′). To obtain a full length clone, rapid amplification of 5′ and 3′ ends (RACE) has been performed ([@bib35]). For the 5′-RACE, successively after mCAP2-specific reverse primers were used: RC1 (5′-ACAGGCAAGGATGGAGAGT-3′, nt position +812 to +794) and adaptor-specific primer dC-5R (5′-GCATGCTCGAGCGGCCGCAACCCCCCCCCCCCCCCCCC-3′), and RC2 (5′-GATGCTCCCACCACAGAC-3′, nt position +696 to +679) and the adaptor-specific primer 5R (5′-GCATGCTCGAGCGGCCGCAAC-3′), according to the manufacturer\'s instructions (Life Technologies). For 3′-RACE, reverse transcription was performed, using mCAP2-specific primers RC3 (5′-GATGAGGTGCTTGTCCCAG-3′, nt position +937 to +955) and an oligo(dt) adaptor primer (5′-CGAGATCTATGCGGCCGCTTTTTTTTTTTTTTTTT-3′). Full-length clone of mCAP2 was obtained by PCR on total RNA extracted from distal colon using S2 (5′-TAGGAGGATTACCAAAGCAG-3′, nt position −20 to −1) and AS2 (5′-ATGCCGTAGGTAGGTCTGAA-3′). 33 cycles were run consisting of 30 s at 94°C, 30 s at 54°C, and 1 min 30 s at 72°C. After the last cycle, elongation was allowed to proceed for 7 min at 72°C using Taq polymerase (Roche). PCR products were purified by gel electrophoresis and, following extraction, cloned into pT7Blue vector (Novagen) and sequenced. The nucleotide sequence reported for mCAP2 in this paper has been submitted to the National Institutes of Health database under EMBL/GenBank/DDBJ accession no. [AY043240](AY043240).

### Mouse CAP3:

By analyzing a SAGE library (serial analysis of genome sequences; [@bib26]) and EST database, a SAGE tag ([GATC]{.ul}AAAGAGCACA) corresponding to the recently cloned mouse epithin (AF042822) had been identified ([@bib15]). Based on sequence information, RT-PCR was performed on RNA of mpkCCD~c14~ cells using primers S3 (5′-GACCACGCGTCTGAGACC-3′, nt position −38 to −20) and AS3 (5′-GACAGTTGGAAGCAGCTCTC-3′, nt position +2868 to +2849). 10 cycles were run, each consisting of 15 s at 94°C, 30 s at 58°C, and 2 min at 68°C, followed by 20 cycles with continuously increasing elongation times of each 20 s at 68°C using Taq polymerase (Expand High Fidelity PCR system; Roche). PCR product was gel purified, extracted, cloned into pT7Blue vector, and named mCAP3.

Northern Blot Analysis
----------------------

Total RNA was prepared from whole mouse kidney and confluent mpkCCD~c14~ cells as described. 20 μg RNA were run on a 0.8% denaturing glyoxal agarose gel and blotted onto nylon membranes (Hybond-N; Amersham Biosciences). Membranes were hybridized with randomly primed ^32^P-labeled probes for rENaC ([@bib5]), mCAP1 (512 bp: nt +163 to +674), mCAP2 (472 bp: nt +643 to +1115), mCAP3 (603 bp: nt +2442 to +3045).

Electrophysiological Experiments in Xenopus Oocytes
---------------------------------------------------

For functional expression studies, cDNA for mCAP1, mCAP2, mCAP3, and mouse Sgk1 (provided by O. Staub, Institute of Pharmacology and Toxicology, Lausanne, Switzerland) were subcloned into pSDS expression vector and in vitro transcribed, as described previously ([@bib5]). Purified cRNA were injected into stage V/VI *Xenopus* oocytes. Routinely, oocytes were injected with 0.33 ng of each cRNA coding for the rat α-, β- and γ-ENaC subunits in the presence or absence of varying concentrations of mCAP1, mCAP2, and mCAP3 and incubated in a modified Barth (low sodium) solution, as described ([@bib13]). Oocytes were incubated overnight in modified Barth saline solution in the presence or absence of 100 μg/ml aprotinin. This protocol insures that intracellular sodium is low at the beginning of the measurement and independent of the level of ENaC expression at the cell surface. Electrophysiological measurements were performed 1--2 d after cRNA injection using the two-electrode voltage-clamp technique and one bath electrode, allowing corrections for serial resistance. The oocytes were exposed to 2 μg/ml trypsin during 2--3 min and amiloride-sensitive Na^+^ current (I~Na~) was measured in the presence of 120 mM of Na^+^ in frog Ringer\'s solution with 5 μM amiloride at a holding potential of −100 mV.

Measurement of N and I~Na~ within the Same Oocyte
-------------------------------------------------

Cell surface expression has been performed as described ([@bib13]). Briefly, 1 ng of tagged rat α-, β-, and γ-ENaC subunits was expressed in oocytes either alone or with 4 ng (mCAP1), 8 ng (mCAP2) or 2 ng (mCAP3) of each CAP and/or 4 ng Sgk1 cRNA. The density of the channel was then calculated by binding of iodinated anti-FLAG monoclonal antibody (M2Ab\*) (Sigma-Aldrich). The binding assay was performed at 4°C, and I~Na~ was measured at room temperature as described. To deduce the whole cell P~o~ (*wc*P~o~), we have used a macroscopic approach, as described ([@bib12]) in which the starting point is the equation, derived from Ohm\'s law: $$\documentclass[10pt]{article}
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\begin{equation*}{\mathrm{I}}_{{\mathrm{Na}}}={\mathrm{g}}_{{\mathrm{Na}}}{\cdot}{\mathrm{N}}{\cdot}{\mathrm{P}}_{{\mathrm{o}}}{\cdot} \left \left({\mathrm{E}}-{\mathrm{E}}_{{\mathrm{Na}}}\right) \right {\mathrm{,}}\end{equation*}\end{document}$$where (a) I~Na~ is the macroscopic amiloride-sensitive current that measures the total activity of all channels expressed in a cell. (b) g~Na~ is the single channel conductance measured by patch clamp in independent experiments. In the presence of sodium it is 5 and 8 pS in the presence of Li ([@bib5]). (c) (E − E~Na~) is assessed by the measurement of membrane potential and the reversal potential for sodium. For practical purposes, E − E~Na~ can be set constant by clamping the membrane at −100 mV or higher, allowing the measurement of changes in P~o~ in function of the various experimental conditions. (d) N is the total number of channel molecules (active and inactive) expressed at the cell surface. The binding assay permits to quantitate the total number of channel molecules at the cell surface, independently of their function. Having determined with good accuracy I~Na~, g~Na~, E − E~Na~, and N, one can deduce a whole-cell P~o~ (*wc*P~o~) that reflects the activity of all channels expressed in an intact whole cell. The main advantage of this macroscopic approach is that it takes into account all channels expressed at the cell surface, whatever their activity. Our method is therefore distinct from a microscopic approach that is the classical measurement of P~o~ in membrane patches (*mp*P~o~). This is performed by determining the overall N · P~o~ of all the active channels and the number of the channels N present in the patch membrane.

Statistical Analysis
--------------------

All results are reported as means ± SEM. Comparing independent sets of data, unpaired *t* tests were used to determine significance. For the measurement of N and I~Na~, a minimum of 3--6 batches of oocytes, 5--10 oocytes per batch, each batch from different animals, were used for each experimental condition. Experiment 1, "ENaC + H~2~O" vs. "ENaC + mCAP1" vs. "ENaC + Sgk1" vs. "ENaC + mCAP1 + Sgk1"; experiment 2, "ENaC + H~2~O" vs. "ENaC + mCAP2" vs. "ENaC + Sgk1" vs. *"*ENaC + mCAP2 + Sgk1"; experiment 3, "ENaC + H~2~O" vs. "ENaC + mCAP3" vs. "ENaC + Sgk1" vs. "ENaC + mCAP3 + Sgk1."

RESULTS
=======

Identification of Two Membrane-bound Serine Proteases in the mpkCCD~cl4~ Cell Line
----------------------------------------------------------------------------------

### mCAP2

By using degenerated oligos to the previously isolated serine protease from *Xenopus* xCAP1 and RACE technique, we identified mCAP2, which encodes a 435--amino acid protein. Analysis of the amino acid sequence and the hydrophobicity plot reveals a type II--oriented membrane-bound serine protease with a predicted transmembrane segment (V30--151) and an extracellular COOH terminus containing a serine protease catalytic domain with the classical catalytic triad at H243, D288, and S385 and with a potential proteolytic activation cleavage site at R202V203 ([Fig. 1](#fig1){ref-type="fig"} A). Two cysteines at position C194 and C308 are predicted to connect the prodomain to the main serine protease domain via a disulfide bond at the extracellular surface of the cell ([@bib14]). The extracellular domain has two potential N-glycosylation sites (N128 and N176) that are used when mCAP2 is expressed in the *Xenopus* oocyte system (unpublished data). The catalytic domain is preceded by a low density lipoprotein receptor class A domain (LDLR, F60-V91) and a group A scavenger receptor domain (SRCR, V102-G142) ([Fig. 1](#fig1){ref-type="fig"} A). The serine protease domain shares homology with mouse trypsinogen precursor (49%), xCAP1 (45%), mCAP1 (43%), and 80% with a human orthologue hTMPRSS4 ([@bib36]) ([Fig. 1](#fig1){ref-type="fig"} B).

![mCAP1, 2, and 3 are membrane-bound serine proteases. (A) Structural properties of the three mCAPs (mCAP1, mCAP2, and mCAP3). The amino acid sequence of each protein was scanned using ProfileScan algorithm to confirm the presence of domains indicated. Numbers delineate the location of each domain. (B) A representative phylogenetic tree of the GPI-anchored mCAP1 and type II transmembrane mCAP2 and mCAP3 serine protease family proteins. Multiple alignment was generated by the clustal W program (mCAP1, AAG1705; hProstasin, Q16651; xCAP1, AAB969054; mCAP2, AY043240; hTMPRSS4-1, CAC60389; hTMPRSS4--2; MT-SP2, Q9NRS4; mTMPRSS2; epitheliasin, AAF97867; hTMPRSS2, AAC51784; mTMPRSS3, CAC83350; hTMPRSS3, P57727; mCAP3; epithin, AAD02230; hMT-SP1, AAF00109; xMT-SP1, BAB08218). (C) Amino acid alignment of the serine protease catalytic domain of mCAP1, mCAP2, and mCAP3 with mouse trypsinogen precursor (1--246), was performed using Pileup program (Genetic Computer Group). Gray and black boxes indicate similar and identical residues, respectively. The catalytic triad (H, D, and S, asterisks), the amino acids implicated in the P1 substrate specificity (closed circle), and the position for Na^+^ sensibility (open circle) are indicated.](20028598f1){#fig1}

### mCAP3

By analysis of the transcriptome of an mpkCCD~cl4~ cell line library by SAGE ([@bib26]) and EST database analysis, we identified a serine protease we termed mCAP3. mCAP3 is identical to the recently cloned mouse epithin ([@bib15]). At the time we started this project, epithin cDNA sequence had not been published. To underline the functional relevance of this serine protease, we name the third serine protease throughout our paper mouse channel--activating protein three (mCAP3). Analysis of the primary sequence revealed the presence of a transmembrane domain with predicted type II orientation ([Fig. 1](#fig1){ref-type="fig"} A). COOH terminus contained the serine protease domain with the catalytic triad (H656, D711, and S805) and a potential activation cleavage site at R605V606. The catalytic domain was preceded by two complement factor IR-urchin embryonic growth factor-bone orphogenetic proteins (CUBs) (C214-F331 and C340-Y444) and four LDLR (C453-R487, C488-S524, C525-N563 and C567-L603) domains ([Fig. 1](#fig1){ref-type="fig"} A) ([@bib15]). mCAP3 shares 47% homology with the mouse trysinogen, 49% with xCAP1, 40% with mCAP2 and 83% with the human orthologue hMT-SP1 ([@bib30]) (or Matriptase; [@bib16]) ([Fig. 1](#fig1){ref-type="fig"} B).

Primary sequence comparison of the catalytic domain of mCAP1, mCAP2, mCAP3, and trypsin revealed the presence of an aspartate (mCAP1, D232; mCAP2, D379; mCAP3, D799) at the S1 site ([@bib28]) and 2 glycines at the entry of the S1 pocket (mCAP1, G259 and G269; mCAP2, G405 and G415; and mCAP3, G827 and G837) which direct the specificity of serine proteases ([@bib24], [@bib25]) ([Fig. 1](#fig1){ref-type="fig"} C). This suggests that all three serine proteases are specific for the positively charged P1 amino acids. The presence of a proline residue (mCAP1, P268; mCAP2, P414; and mCAP3, P836) instead of a tyrosine residue at the Na^+^-induced allosteric regulation of catalytic activity site in serine proteases suggests that the catalytic activity of three serine proteases is not sensitive to extracellular Na^+^ concentration variations ([@bib8]) ([Fig. 1](#fig1){ref-type="fig"} C).

Northern blot analysis showed that mCAP1, mCAP2, mCAP3, and αENaC subunit are expressed, as expected, in mpkCCD~c14~ cell line. Whereas mCAP3 expression was expressed in the cell line and the kidney at a level similar to that of mCAP1, mCAP2 expression was low and not detectable in the whole kidney ([Fig. 2](#fig2){ref-type="fig"}) . The three membrane-bound proteases and the αENaC subunit were also expressed in epithelia known to express an amiloride-sensitive sodium transport (lung and colon). A similar pattern of expression was also found in small intestine and stomach. In these tissues, the role of ENaC and/or CAPs remains to be established.

![Coexpression of all three serine proteases with ENaC. Multiple tissue Northern blot containing 20 μg of RNA/lane were hybridized with cDNA fragments of the rat αENaC, mouse CAP1, CAP2, CAP3, and GAPDH genes, as described in [materials]{.smallcaps} [and]{.smallcaps} [methods]{.smallcaps}. mRNA transcript lengths are indicated.](20028598f2){#fig2}

ENaC Activation by mCAP1, mCAP2, and mCAP3 in Xenopus Oocytes
-------------------------------------------------------------

In the *Xenopus* oocytes, ENaC activity is recorded as an amiloride-sensitive Na^+^ current (I~Na~). As shown in [Fig. 3](#fig3){ref-type="fig"} A (lanes 1--4), mCAP1 increased ENaC activity 5--10-fold. Increasing amounts of cRNA coding for mCAP1 were tested and a maximal effect was observed with 4 ng mCAP1. mCAP2 and mCAP3 ([Fig. 3](#fig3){ref-type="fig"}, lanes 5--8 and 9--12) were also able to increase ENaC activity by 4--8-fold, the maximal effect for mCAP2 was observed with 8 ng of injected cRNA and for mCAP3 with only 2 ng cRNA. At higher concentrations of mCAP3 (4--12 ng), ENaC activation was inhibited, (P \< 0.01) presumably by competition for the translational machinery. Consequently, in all further experiments we used 4 ng (mCAP1), 8 ng (mCAP2), and 2 ng (mCAP3) that induce maximal activation of ENaC.

![Functional analysis of mCAP1--3 in *Xenopus* oocytes. (A) Comparison of the effect of mCAP1, mCAP2, and mCAP3 on I~Na~ in *Xenopus* oocytes. Oocytes were injected with rat ENaC subunits in the presence of either water (open bar, lane 1) or increasing amounts (2, 4, and 8 or 12 ng) of mCAP1 (closed bar, lanes 2--4), mCAP2 (light gray bar, lanes 5--8), or mCAP3 (dark gray bars, lanes 9--12). §§, P \< 0.01 versus conditions with other amounts of the same cRNA protease. *n* ≥ 12 measured oocytes. (B) Effect of preincubation with aprotinin (lanes 3, 4, 7, 8, 11, 12, 15, 16) or perfusion of trypsin (gray bars, lanes 2, 4, 6, 8, 10, 12, 14, 16) on oocytes injected with either rENaC and water (lane 1--4) or rENaC together with 4 ng mCAP1 (lane 5--8), 8 ng mCAP2 (lane 9--12), and 2 ng mCAP3 (lane 13--16). *n* ≥ 12 measured oocytes.](20028598f3){#fig3}

Trypsin can activate the I~Na~ ([Fig. 3](#fig3){ref-type="fig"} B, lane 2 vs. 1). The activity of ENaC can be partially blocked by incubating the oocytes in the presence of the serine protease inhibitor aprotinin (lane 3), suggesting that ENaC has been weakly activated by endogenous serine proteases. This block can be overcome by further addition of trypsin in the medium (lane 4). Activation of ENaC in the presence of mCAP1 (lane 5) cannot be further increased by trypsin (lane 6), whereas preincubation in the presence of aprotinin inhibits ENaC activity to base line level (lane 7), which can then be restored by trypsin (lane 8). In the same assay, one can observe that mCAP2 similarly activates ENaC (lanes 9--12). mCAP3 was also able to fully activate ENaC (lane 13), to a level that was not further increased by trypsin (lane 14). Unlike mCAP1 or mCAP2, this effect was aprotinin resistant (lane 15) and could not be further increased by perfusion of trypsin (lane 16). These data indicate that the mCAP3 aprotinin binding site, unlike that of mCAP1 and mCAP2, has a low affinity for the inhibitor. mCAP3 is therefore a good candidate for being a serine protease responsible for the aprotinin-resistant component observed in mpkCCD~c14~ cells.

Functional Interaction between CAPs and Sgk1 in the Xenopus Oocyte System
-------------------------------------------------------------------------

To test whether mouse CAPs and Sgk1 interact functionally, oocytes injected with rENaC FLAG-tagged subunits (rENaCf) were coexpressed either individually or with each protease (mCAP), or with Sgk1 or both together. If the two activation pathways are fully independent of each other but have a final common effector (ENaC), a true potentiation should be observed, i.e., any synergistic effect should be more than additive. In [Table I](#tbl1){ref-type="table"} (mCAP1-Skg1), [Table II](#tbl2){ref-type="table"} (mCAP2-Sgk1), [Table III](#tbl3){ref-type="table"} (mCAP3 + Sgk1), the data are presented in absolute values, allowing to quantify the synergism observed.

###### 

Effect of Sgk1 and CAP1 on ENaC-mediated Sodium Current (I~Na~) and Cell Surface Expression (N) Measured by Monoclonal Antibody Binding to Flagged αβγENaC

                                             Before trypsin treatment   After trypsin treatment                               
  --------------------- ---- --------------- -------------------------- ------------------------- ------------ -------------- -----------------
                                             μA/oocyte                  μA/f mole                 μA/oocyte    μA/f mole      
  ENaC + H~2~O          40   0.085 ± 0.007   1.1 ± 0.2                  14.2 ± 1.0                6.2 ± 1.0    84.1 ± 12.3    5.9 (P \< 0.01)
  ENaC + mCAP1          35   0.085 ± 0.010   11.9 ± 1.5                 182.6 ± 24.3              11.4 ± 1.5   175.9 ± 23.3   1.0 (ns)
  ENaC + Sgk1           31   0.139 ± 0.014   2.7 ± 0.4                  21.7 ± 2.9                12.0 ± 1.6   102.9 ± 14.2   4.7 (P \< 0.01)
  ENaC + Sgk1 + mCAP1   26   0.186 ± 0.015   24.5 ± 1.8                 162.8 ± 21.2              24.4 ± 1.7   149.3 ± 14.1   0.9 (ns)

I~Na~ and N were measured in the same oocyte as described in [materials]{.smallcaps} [and]{.smallcaps} [methods]{.smallcaps}. 26--40 oocytes from a minimum of 5 different batches were measured for each experimental condition.

*t* test results for N: control vs. CAP1, P \< 0.9; control vs. Sgk1, P \< 0.001; control vs. Sgk1 + mCAP1, P \< 0.001; mCAP1 vs. Sgk1, P \< 0.001; mCAP1 vs. Sgk1 + mCAP1, P \< 0.001; Sgk1 vs. Sgk1 + mCAP1, P \< 0.02.

*t* test results for I~Na~: control vs. CAP1, P \< 0.001; control vs. Sgk1, P \< 0.001; control vs. Sgk1 + mCAP1, P \< 0.001; mCAP1 vs. Sgk1, P \< 0.001; mCAP1 vs. Sgk1 + mCAP1, P \< 0.001; Sgk1 vs. Sgk1 + mCAP1, P \< 0.001.

*t* test results for I~Na~/N: control vs. CAP1, P \< 0.001; control vs. Sgk1, P \< 0.03; control vs. Sgk1 + mCAP1, P \< 0.001; mCAP1 vs. Sgk1, P \< 0.001; mCAP1 vs. Sgk1 + mCAP1, P \< 0.55; Sgk1 vs. Sgk1 + mCAP1, P \< 0.001.

###### 

Effect of Sgk1 and CAP2 on ENaC-mediated Sodium Current (I~Na~) and Cell Surface Expression (N) Measured by Monoclonal Antibody Binding to Flagged αβγENaC

                                             Before trypsin treatment   After trypsin treatment                               
  --------------------- ---- --------------- -------------------------- ------------------------- ------------ -------------- -----------------
                                             μA/oocyte                  μA/f mole                 μA/oocyte    μA/f mole      
  ENaC + H~2~O          32   0.065 ± 0.008   0.5 ± 0.1                  10.1 ± 1.5                3.9 ± 0.9    73.3 ± 13.8    7.3 (P \< 0.01)
  ENaC + mCAP2          28   0.070 ± 0.007   4.2 ± 0.9                  90.0 ± 23.0               4.9 ± 0.9    94.2 ± 20.0    1.0 (ns)
  ENaC + Sgk1           26   0.105 ± 0.016   1.2 ± 0.1                  24.1 ± 7.2                6.4 ± 0.7    106.2 ± 18.9   4.4 (P \< 0.01)
  ENaC + Sgk1 + mCAP2   19   0.151 ± 0.018   9.1 ± 1.3                  80.7 ± 14.8               12.4 ± 1.1   108.4 ± 16.3   1.3 (ns)

I~Na~ and N were measured in the same oocyte as described in [materials]{.smallcaps} [and]{.smallcaps} [methods]{.smallcaps}. 19--32 oocytes from a minimum of 5 different batches were measured for each experimental condition.

*t* test results for N: control vs. CAP2, P \< 0.6; control vs. Sgk1, P \< 0.02; control vs. Sgk1 + mCAP2, P \< 0.001; mCAP2 vs. Sgk1, P \< 0.04; mCAP2 vs. Sgk1 + mCAP2, P \< 0.001; Sgk1 vs. Sgk1 + mCAP2, P \< 0.06.

*t* test results for I~Na~: control vs. CAP2, P \< 0.001; control vs. Sgk1, P \< 0.001; control vs. Sgk1 + mCAP2, P \< 0.001; mCAP2 vs. Sgk1, P \< 0.001; mCAP2 vs. Sgk1 + mCAP2, P \< 0.003; Sgk1 vs. Sgk1 + mCAP2, P \< 0.001.

*t* test results for I~Na~/N: control vs. CAP2, P \< 0.001; control vs. Sgk1, P \< 0.04; control vs. Sgk1 + mCAP2, P \< 0.001; mCAP2 vs. Sgk1, P \< 0.01; mCAP2 vs. Sgk1 + mCAP2, P \< 0.8; Sgk1 vs. Sgk1 + mCAP2, P \< 0.001.

###### 

Effect of Sgk1 and CAP3 on ENaC-mediated Sodium Current (I~Na~) and Cell Surface Expression (N) Measured by Monoclonal Antibody Binding to Flagged αβγENaC

                                             Before trypsin treatment   After trypsin treatment                               
  --------------------- ---- --------------- -------------------------- ------------------------- ------------ -------------- -----------------
                                             μA/oocyte                  μA/f mole                 μA/oocyte    μA/f mole      
  ENaC + H~2~O          34   0.067 ± 0.008   0.5 ± 0.1                  9.3 ± 1.4                 2.9 ± 0.5    62.8 ± 12.1    6.7 (P \< 0.01)
  ENaC + mCAP3          15   0.061 ± 0.013   3.4 ± 0.5                  87.6 ± 20.1               4.4 ± 0.6    101.9 ± 17.5   1.2 (ns)
  ENaC + Sgk1           28   0.122 ± 0.015   1.8 ± 0.3                  18.6 ± 2.7                8.7 ± 1.1    99.2 ± 15.4    5.3 (P \< 0.01)
  ENaC + Sgk1 + mCAP3   30   0.140 ± 0.014   13.2 ± 1.1                 141.3 ± 20.7              15.7 ± 1.5   150.8 ± 18.4   1.1 (ns)

I~Na~ and N were measured in the same oocyte as described in [materials]{.smallcaps} [and]{.smallcaps} [methods]{.smallcaps}. 15--34 oocytes from a minimum of 5 different batches were measured for each experimental condition.

*t* test results for N: control vs. CAP3, P \< 0.7; control vs. Sgk1, P \< 0.001; control vs. Sgk1 + mCAP3, P \< 0.001; mCAP3 vs. Sgk1, P \< 0.01; mCAP3 vs. Sgk1 + mCAP3, P \< 0.001; Sgk1 vs. Sgk1 + mCAP3, P \< 0.4.

*t* test results for I~Na~: control vs. CAP3, P \< 0.001; control vs. Sgk1, P \< 0.001; control vs. Sgk1 + mCAP3, P \< 0.001; mCAP3 vs. Sgk1, P \< 0.003; mCAP3 vs. Sgk1 + mCAP3, P \< 0.001; Sgk1 vs. Sgk1 + mCAP3, P \< 0.001.

*t* test results for I~Na~/N: control vs. CAP3, P \< 0.001; control vs. Sgk1, P \< 0.002; control vs. Sgk1 + mCAP3, P \< 0.001; mCAP3 vs. Sgk1, P \< 0.001; mCAP3 vs. Sgk1 + mCAP3, P \< 0.1; Sgk1 vs. Sgk1 + mCAP3, P \< 0.001.

mCAP1 and Sgk1
--------------

When rENaCf was coexpressed with mCAP1 ([Table I](#tbl1){ref-type="table"}), N did not change (P \< 0.9) (column a) whereas I~Na~ (column b) increased 11-fold (P \< 0.001) compared with rENaCf expressed alone. When rENaCf was coexpressed with Sgk1, we observed a 1.6-fold in N (P \< 0.01) and a 2.6-fold increase in I~Na~ (P \< 0.001). When Sgk1 and mCAP1 were coexpressed, I~Na~ increased 9.1-fold (P \< 0.001) and N by only 0.3-fold (P \< 0.05) when compared with oocytes injected with Sgk1 alone. If the effect of the two pathways was just additive, their combined effect would not exceed the sum of the two cRNA given alone. For I~Na~ it should not exceed 13 μA per oocyte, but we do observe 24 μA/oocyte. Thus, the data indicate a strong and highly significant (P \< 0.001) potentiation between mCAP1 and Sgk1 for the I~Na~ effect, whereas the synergism for the N effect was small (though significant) and less than additive. To verify that mCAP1 was expressed for its maximal effect, we tested the effect of external trypsin. As shown in [Table I](#tbl1){ref-type="table"}, trypsin (column d) was able to increase baseline I~Na~ only in ENaC or ENaC + Sgk1--injected oocytes. By contrast, trypsin did not elicit any further increase in I~Na~ when mCAP1 was expressed. These data indicate that mCAP1 has already fully activated ENaC expressed at the surface of the oocyte. I~Na~/N (column c) is a parameter from which one can deduce the average open probability in a whole cell *wc*P~o~ (see [materials]{.smallcaps} [and]{.smallcaps} [methods]{.smallcaps} and [discussion]{.smallcaps}). As shown in [Table I](#tbl1){ref-type="table"}, mCAP1 increased I~Na~/N by 13-fold (P \< 0.001), Sgk1 alone had a minimal effect (1.5-fold; P \< 0.05), mCAP1 and Sgk1 lead to an 11-fold increase in I~Na~/N (P \< 0.001), not significantly different from stimulation observed with CAP1 alone. Upon activation by trypsin (column e), I~Na~/N increased 5.9-fold in controls (P \< 0.001) and 4.7-fold in Sgk1 injected oocytes (P \< 0.001). No further significant increase in I~Na~/N was observed in mCAP1 or mCAP1 + Sgk1--coinjected oocytes.

mCAP2 and Sgk1
--------------

When rENaCf was coexpressed with mCAP2 ([Table II](#tbl2){ref-type="table"}), N did not change (P = 0.6) (column a), whereas I~Na~ (column b) increased 8.4-fold (P \< 0.001) compared with rENaCf expressed alone. When rENaCf was coexpressed with Sgk1, we observed a 1.6-fold increase in N (P \< 0.01) and a 2.4-fold increase in I~Na~ (P \< 0.001). When Sgk1 and CAP2 were coexpressed, I~Na~ increased 7.6-fold (P \< 0.001) and N by 1.4-fold (P \< 0.06) when compared with oocytes injected with Sgk1 alone. If the effect of the two pathways was just additive, their combined effect would not exceed the sum of the two cRNA given alone. For I~Na~ it should not exceed 5.4 μA/oocyte, but we do observe 9.1 μA/oocyte. Thus, the data indicate a strong and highly significant (P \< 0.001) potentiation between mCAP2 and Sgk1 for the I~Na~ effect, whereas the synergism for the N effect did not reach the level of significance (P \< 0.06) and was less than additive. To verify that mCAP2 was expressed maximally, we tested the effect of external trypsin. As shown in [Table II](#tbl2){ref-type="table"}, trypsin (column d) was able to increase baseline I~Na~ only in ENaC or ENaC + Sgk1--injected oocytes. By contrast, trypsin did not elicit any further increase in I~Na~ when mCAP2 was expressed. These data indicate that mCAP2 has already fully activated ENaC expressed at the surface of the oocyte. As shown in [Table II](#tbl2){ref-type="table"} (column d), mCAP2 increased I~Na~/N by ninefold (P \< 0.001), Sgk1 alone had a small effect (2.4-fold; P \< 0.05), and mCAP2 and Sgk1 led to a 10-fold increase in I~Na~/N (P \< 0.001), not significantly different from the stimulation observed with mCAP2 alone (P \< 0.76). Upon activation by trypsin (column e), I~Na~/N increased 7.3-fold in controls (P \< 0.001) and 4.4-fold in Sgk1-injected oocytes (P \< 0.001). No further significant increase in I~Na~/N was observed in mCAP2 or mCAP2 + Sgk1--coinjected oocytes.

mCAP3 and Sgk1
--------------

When rENaCf was coexpressed with mCAP3 ([Table III](#tbl3){ref-type="table"}), N did not change (P \< 0.7) (column a), whereas I~Na~ (column b) increased 6.8-fold (P \< 0.001) compared with rENaCf expressed alone. When rENaCf was coexpressed with Sgk1, we observed a 1.8-fold increase in N (P \< 0.001) and a 3.6-fold increase in I~Na~ (P \< 0.001). When Sgk1 and mCAP3 were coexpressed, I~Na~ increased 7.3-fold (P \< 0.001) and N by only 0.14-fold (P = 0.4) compared with oocytes injected with Sgk1 alone. If the effect of the two pathways was just additive, their combined effect would not exceed the sum of the two cRNAs given alone. For I~Na~, it should not exceed 5.2 μA/oocyte, but we do observe 13.2 μA/oocyte. Thus, the data indicate a strong and highly significant (P \< 0.001) potentiation between mCAP3 and Sgk1 for the I~Na~ effect, whereas the synergism for the N effect was significant but small and less than additive. To verify that mCAP3 was expressed maximally, we tested the effect of external trypsin. As shown in [Table III](#tbl3){ref-type="table"}, trypsin (column d) was able to increase baseline I~Na~ only in ENaC or ENaC + Sgk1--injected oocytes. By contrast, trypsin did not elicit any further increase in I~Na~ when mCAP3 was expressed alone or with Sgk1. These data indicate mCAP3 has already fully activated ENaC expressed at the surface of the oocyte. As shown in [Table III](#tbl3){ref-type="table"}, mCAP3 increased I~Na~/N by 9.4-fold (P \< 0.001), Sgk1 alone had a small effect (twofold (P \< 0.01), and mCAP3 and Sgk1 led to 7.6-fold increase in I~Na~/N (P \< 0.001), not significantly different from stimulation observed with CAP3 alone (P \< 0.14). Upon activation by trypsin (column e), I~Na~/N increased 6.7-fold in controls (P \< 0.001) and 5.3-fold in Sgk1-injected oocytes (P \< 0.001). No further significant increase in I~Na~/N was observed in mCAP3 or mCAP3 + Sgk1--coinjected oocytes.

In summary, qualitatively, the effects of mCAP1, mCAP2, or mCAP3 are remarkably similar. Since baseline I~Na~ varies by a factor of two from experiment to experiment (see column b, ENaC-injected oocytes of each table), comparisons between CAPs are also shown in [Fig. 4](#fig4){ref-type="fig"} and summarized as relative changes normalized to ENaC and/or water-injected oocytes. It is evident that, when corrected for the different baseline values, the effects of each CAP are also quantitatively very similar.

![Synergistic activation of mCAP1--3 and Sgk1 on ENaC activity. (A) Oocytes were injected with cRNA coding either for α, β, and γFLAG-tagged rENaC subunits (rENaCf) and water (lane 1) or rENaCf together with mCAP1 (lane 2), mCAP2 (lane 3), mCAP3 (lane 4), Sgk1 (lanes 5--8), or both Sgk1 and mCAP1 (lane 6), Sgk1 and mCAP2 (lane 7), and Sgk1 and mCAP3 (lane 8). I~Na~ was measured in absence (open bar) and after perfusion of trypsin (closed bar) and normalized to I~Na~ in oocytes injected with rENaC alone. *n* ≥ 15 measured oocytes per experimental condition taken from [Tables I](#tbl1){ref-type="table"}--III. (B) Normalized oocyte cell surface expression of rENaCf in oocytes experiments described in A. Water, lane 1; mCAP1, lane 2; mCAP2, lane 3; mCAP3, lane 4; Sgk1, lane 5; mCAP1 + Sgk1, lane 6; mCAP2 + Sgk1, lane 7; mCAP3 + Sgk1, lane 8. \*\*\*, P \< 0.001 versus rENaCf + water.](20028598f4){#fig4}

DISCUSSION
==========

Membrane-bound Serine Proteases: a Novel Signaling Cascade in Epithelial Cells?
-------------------------------------------------------------------------------

In this study, we describe the identification of three distinct mammalian membrane-bound serine proteases that are present in the same cell type. mCAP1 is a GPI-anchored protein, whereas mCAP2 and mCAP3 belong to the type 2 transmembrane serine proteases (TTSPs) family ([@bib14]). A few members of membrane-bound serine proteases have been so far biochemically characterized or their cell surface localization has been demonstrated ([@bib14]). Based on a conserved disulfide bond linking the pro- and the catalytic domains, one can predict that TTSPs are active in their membrane-bound form. Interestingly, some TTSPs have a high degree of autocatalytic activity and the targeting of the TTSPs to the apical membrane of an epithelial cell involves its proteolytic domain ([@bib40]; [@bib14]). Recently, a recombinant Kunitz-type serine protease inhibitor, which is similar to aprotinin, was tested in human bronchial epithelial cells and shown to efficiently block ENaC-mediated Na^+^ transport in the lung ([@bib4]). Homology screening of a human airway epithelial cDNA library identified human prostasin (the orthologue of mCAP1) and TMPRSS2, a homologue of mCAP2 or the human TMPRSS4 ([@bib10]). These authors demonstrated that prostasin increased ENaC activity, whereas TMPRSS2 had a strong antagonist effect in the *Xenopus* oocyte system. In our screen, we were not able to identify epitheliasin, the mouse homologue of TMPRSS2, in the mpkCCD~c14~ cell line. In our study, mCAP2 clearly has an agonist effect on ENaC activation, which is very similar to that of mCAP1 or prostasin. It is not clear, at present time, what the structural difference is between the two proteases that might explain this striking functional difference. Our present working hypothesis is that mCAP1--3 are coexpressed at the apical membrane of, for example, kidney cells, and exert their effect either together on channel activation or by a catalytic cascade similar to the serine protease cascade of the blood clotting system. For xCAP1, we have reported recently the importance of the GPI anchor for the activation of ENaC at the plasma membrane ([@bib33]), but the role of the transmembrane domains of mCAP2 or mCAP3 in ENaC activation has not yet been studied. How and in which sequence each of the serine proteases may activate ENaC is not known.

Control of Cell Surface Expression of ENaC and its Open Probability by Two Distinct and Synergistic-signaling Pathways Extends the Dynamic Range of Channel Regulation
----------------------------------------------------------------------------------------------------------------------------------------------------------------------

The *Xenopus* oocyte expression system allows to quantify cell surface expression of epithelial sodium channels and to determine the channel open probability in a whole cell (*wc*P~o~) ([@bib13], [@bib12]) (see [materials]{.smallcaps} [and]{.smallcaps} [methods]{.smallcaps}). According to the single channel measurement after trypsin activation reported by [@bib7], one can make the assumption that gNa remains unchanged under our experimental conditions. Under a voltage clamp set constant at −100 mV, one can now get a fairly good estimate of the *wc*P~o~ and how it is affected by our experimental maneuvers. Under low sodium incubation, we reported a I~Na~/N of 4.82 mA/fmole ([@bib13]). We can calculate a *wc*P~o~ of around 0.018, assuming a heterotetrameric channel ([@bib11]). In the present study, we injected three times less ENaC cRNA, leading to a lower cell surface expression of ENaC (N varies from 0.06--0.08 fmole/oocyte \[present study\] vs. 0.5 fmole/oocyte \[Firsov et al., 1998\]) but with a relatively high current (I~Na~, 0.5--1 μA/oocyte with a I~Na~/N varying between 9 and 14 μA/fmole (See Table I--III). From these data, one can calculate a *wc*P~o~ of 0.05. For ENaC, the estimation of P~o~ in membrane patches (*mp*P~o~) has been reported to be extremely variable ([@bib22]; [@bib23]). In native membranes from salt-repleted rat, no channel activity was detectable. It is likely that this observation is due to the lack of sensitivity of the patch method to detect channels with very low P~o~ or very few channels with higher P~o~. In native membrane from salt-depleted animals with high plasma aldosterone levels, *mp*P~o~ ranged from 0.05 to 0.9 with an average value of 0.5 ([@bib21]). Due to the wide distribution of spontaneous P~o~ and the slow transitions between open and closed states, the quantitation of the number of active channels in the membrane patch is difficult, leading to overestimation of P~o~. This overestimation could be experimentally documented by direct comparisons of the two methods for a mutant channel of the β subunit (G37S) leading to a 50% decrease in Po ([@bib12]). The alternative *wc*P~o~ method used in the present study is therefore a useful quantitative approach to assess the effect of CAP or Sgk1 on P~o~ in an intact cell.

mCAP1, mCAP2, and mCAP3 Increase wcP~o~ without Changing N
----------------------------------------------------------

Upon CAP stimulation, it is evident that the *wc*P~o~ of ENaC can reach very high values (up to 0.65 for mCAP1), which cannot be further increased by external trypsin. None of the three CAPs tested changed the cell surface expression of ENaC. It would appear that this signaling pathway is unique in controlling the gating of the channel from an external site, which is trypsin sensitive ([@bib7]). The molecular mechanisms remain elusive. It has been suggested that the γ subunit was a substrate for CAP ([@bib18]) but, so far, no biochemical experimental evidence has supported this hypothesis. A second important issue is to know whether CAPs are regulated by hormones or other factors. In our experimental systems, we have not been able to demonstrate any effect of aldosterone on the mRNA abundance of either of the three CAPs expressed in mpkCCD cells (unpublished data). It is, however, interesting to note a recent article reporting that aldosterone increased in vitro the expression of mCAP1/prostasin mRNA and protein in a kidney cell line (M1) and in vivo in adrenalectomized rats ([@bib20]).

Dual Effect of Sgk1 on N and wcP~o~
-----------------------------------

Our data clearly indicate that Sgk1 increases N significantly in three large and independent series of experiments (Table I--III and [Fig. 4](#fig4){ref-type="fig"}), confirming previous reports showing an over twofold increased expression of αβγ-FLAG ENaC measured by ^125^I-protein G binding to the anti-FLAG monoclonal antibody ([@bib2]), with no evidence of an effect on P~o~ measured in membrane patches. More recently, it has been shown that Sgk1 induced a proportional increase in I~Na~ and in N (about threefold) in the *Xenopus* oocyte system, suggesting that the effect is entirely mediated by a change in ENaC cell-surface expression ([@bib17]) that may occur in vivo only in a restricted part of the aldosterone-sensitive distal nephron (proximal ASDN). Our data differ somewhat from these two studies in the sense that we do observe a small but highly significant and highly reproducible effect of Sgk1 on I~Na~/N (1.52, P \< 0.001, [Table I](#tbl1){ref-type="table"}; 2.4, P \< 0.001 Table II; and 2.0, P \< 0.001) that is consistently higher than that observed on N ([Table III](#tbl3){ref-type="table"}), suggesting that Sgk1 has an additional effect on *wc*P~o~. The reasons for that difference are not clear, but our experimental protocol differs significantly from those of the two previous studies in the sense that we have measured I~Na~ and N in the same individual oocyte, allowing a better quantitation of any effect on N and/or P~o~. On the other hand, values of *mp*P~o~ reported in one study were 0.83 for ENaC-injected oocytes and 0.87 for ENaC + Sgk1--injected oocytes ([@bib2]). As discussed above, such high baseline values may not reflect the physiological regulation of ENaC in a kidney cell and the technique may underestimate the number of silent or weakly active channels in the membrane. Interestingly, we reported previously that the Liddle mutation has also a dual effect on N and P~o~ ([@bib13]), very similar to the effect of Sgk1 reported here. Since Sgk1 is proposed to mediate its effects on ENaC through the phosphorylation of Nedd4--2 ([@bib9]), which binds to the PPXY motif of ENaC, which is precisely the consensus for the Liddle mutation, it would make sense that the Sgk1-Nedd4-2-ENaC--signaling cascade involves a dual mechanism of ENaC activation.

CAP and Sgk1: Synergism of Potentiation
---------------------------------------

This paper demonstrates a synergism between the two signaling pathways in the oocyte expression system ([Figs. 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}) . mCAP1, mCAP2, or mCAP3 have no effect on cell surface expression of ENaC, but increase *wc*P~o~ by 7--10-fold. On the other hand, Sgk1 increases the number of channels expressed at the cell surface by twofold, without changing *wc*P~o~. When the two signaling pathways are activated together, a 20--30-fold increase is observed. The synergism is therefore more than additive and is a true potentiation. The possible mechanisms for this synergism has not yet been studied. It will be interesting to examine whether mCAPs can bind directly to ENaC by protein--protein interaction through their extracellular (mCAP1, mCAP2, or mCAP3) and/or through their cytoplasmic domains (mCAP2 or mCAP3). Another possible mechanism would imply a protein--protein interaction between Sgk1 and the intracellular COOH termini of mCAP2 or mCAP3 as a potential target for phosphorylation. It remains to demonstrate that the synergism we describe here operates in vivo in the principal cell of CCD in response to aldosterone. Gene inactivation of Sgk1 ([@bib38]) and mCAP1 ([@bib27]), mCAP2, and mCAP3 will help to dissect the respective role of the two signaling pathways. Despite large variations in salt intake, the kidney is able to maintain sodium balance and the extracellular volume within narrow margins, an important factor in the control of blood pressure. The ASDN plays a key role in adjusting sodium reabsorption to diet intake that may vary from 1 g NaCl/d to 40 g/d. The fine control of ENaC through the control of its cell surface expression and its open probability by aldosterone acting, on one hand, on an intracellular signaling cascade and, on the other hand, on a serine protease that controls gating from the extracellular compartment, should provide the large range required for rapid and long term regulation of sodium transport in ASDN.

![Model of CAPs and Sgk1 action on ENaC. (A) CAPs increase the open probability of ENaC channels. The substrate of CAPs may be ENaC or protein(s) associated with ENaC. (B) Model of Sgk1 action on ENaC. Sgk1 principally increases the number of active channels at the cell surface by diminishing the removal of the channels from the cell surface and by increasing its P~o~. (C) CAPs proteases and Sgk1 act synergically on the channel open probability and cell surface expression.](20028598f5){#fig5}

We thank Jean-Daniel Horisberger, Laurent Schild, Dmitri Firsov, and Olivier Staub for critically reading the manuscript and Nicole Skarda for secretarial work.

This work was supported by grants from the Swiss National Foundation (\#31-063801.00 to E. Hummler and \#31-061966.00 to B. Rossier).

*Abbreviations used in this paper:* ASDN, aldosterone-sensitive distal nephron; ENaC, epithelial sodium channel; mCAP, mouse channel--activating protease; TTSP, type 2 transmembrane serine protease.

[^1]: Address correspondence to Bernard C. Rossier, Institut de Pharmacologie et de Toxicologie, Rue du Bugnon 27, CH-1005 Lausanne, Switzerland. Fax: (41) 21-692-5355; E-mail: <Bernard.Rossier@ipharm.unil.ch>
